Andromeda Biotech Initiates DIA-AID 2, a Confirmatory Phase 3 Study using DiaPep277, for the Treatment of Type 1 Diabetes
Enrollment of patients has begun in the US as part of a global trial which will be conducted at 100 medical centers in North America, Europe, and Israel. This confirmatory study will include 450 newly diagnosed type 1 diabetes patients 20-45 years of age. The study is double-blind, placebo-controlled with a treatment period of 24 months. The main goal of the study is to maintain the ability of the pancreas to secrete insulin in patients who receive treatment with DiaPep277® compared to the placebo group.
Shlomo Dagan, CEO of Andromeda commented, “We are very pleased to achieve this important milestone as part of our clinical development plan for DiaPep277®, which was accepted by the EMA and the FDA. Notably, the success of this study will enable us to obtain marketing approval of the drug in Europe and the USA.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.